Grifols (NASDAQ:GRFS) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS) from a hold rating to a buy rating in a report published on Saturday,Wall Street Zen reports.

GRFS has been the topic of a number of other research reports. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $10.00.

Grifols Price Performance

Grifols stock opened at $7.31 on Friday. Grifols has a 12 month low of $6.96 and a 12 month high of $10.23. The company has a current ratio of 2.37, a quick ratio of 0.81 and a debt-to-equity ratio of 1.10. The business’s 50 day simple moving average is $7.75 and its 200 day simple moving average is $7.83. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 38.47, a PEG ratio of 0.27 and a beta of 0.67.

Hedge Funds Weigh In On Grifols

A number of large investors have recently made changes to their positions in GRFS. Versant Capital Management Inc raised its stake in shares of Grifols by 36.0% during the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,842 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Grifols by 50.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 2,998 shares in the last quarter. Allworth Financial LP boosted its stake in Grifols by 15.7% in the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 1,096 shares during the period. OLD National Bancorp IN bought a new position in Grifols in the 1st quarter worth about $104,000. Finally, Compass Wealth Management LLC purchased a new position in Grifols during the 2nd quarter valued at about $108,000.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.

Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases.